Answer
Breastfeeding should be discontinued throughout treatment with loncastuximab tesirine (Zynlonta) and for at least 3 months after the last dose.
Sources for this answer
- Zynlonta, 10mg, powder for concentrate for solution for infusionSwedish Orphan Biovitrum Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 6Document updated
Sources checked